— Matinas BioPharma (NYSE: MTNB) reported loss of $0.04 per share in the fourth quarter of 2019, vs $0.03 per share loss expected.
— Initiated ENHANCE-IT study of MAT9001 against Vascepa. Topline data expected Q4 2020.
— Cash, cash equivalents and marketable securities at December 31, 2019 were approx. $27.8 million, compared to $12.4 million a year ago.
— MTNB shares ended down 2.75% in its last trading session on Friday.
General Mills Inc. (NYSE: GIS) reported fourth quarter 2022 earnings results today. Net sales increased 8% year-over-year to $4.9 billion. Organic net sales rose 13%. Net earnings attributable to General
Shares of KB Home (NYSE: KBH) have dropped 35% year-to-date and 28% over the past 12 months. Last week, the company reported second quarter 2022 earnings results that surpassed expectations
Trade Desk, Inc. (NASDAQ: TTD) has remained a much sought-after demand-side platform despite challenging market conditions and growing inflationary pressure, but its stock suffered heavy selling in recent months. The